VCYT Insider Filing: Stapley Withholds 7,914 Shares for Taxes

Rhea-AI Filing Summary

Marc Stapley, who is listed as both Chief Executive Officer and a director of Veracyte, Inc. (VCYT), reported a non-sale withholding of 7,914 shares of common stock on 09/02/2025 at an attributable price of $30.11 per share. The withholding satisfied tax obligations arising from the vesting of restricted stock units and therefore was not a market sale. After the transaction Stapley beneficially owned 341,852 shares, which includes 529 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 09/04/2025.

Positive

• Withholding was used to satisfy tax obligations rather than a sale, indicating the reporting person did not reduce ownership via market sale.
• Reporting shows continued significant insider ownership with 341,852 shares beneficially owned after the transaction.

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine tax-withholding on RSU vesting; no sale proceeds, modest impact on insider ownership.

This report documents a common administrative transaction where 7,914 shares were withheld to satisfy tax withholding from vested restricted stock units rather than sold on the open market. The withholding reduces the reporting person’s outstanding vested shares by the withheld amount but does not alter the economic exposure from vested equity that remains held. With beneficial ownership of 341,852 shares post-transaction, the move appears routine and non-dilutive from an investor perspective.

Corporate Governance Expert

TL;DR: Filing reflects standard executive compensation mechanics, signaling retention rather than disposition.

The Form 4 shows an administrative compliance action to cover taxes on RSU vesting, not a disposition. Such withholdings are consistent with typical equity compensation plans and indicate the reporting person retained the remaining vested shares. The filing’s clarity about the ESPP purchase and the attorney-in-fact signature meets disclosure expectations for timeliness and completeness.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stapley Marc

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	7,914	$30.11	$238K

Holdings After Transaction: Common Stock — 341,852 shares (Direct)

Footnotes (1)

1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2025 and does not represent a sale. Includes 529 shares of common stock purchased on July 31, 2025 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stapley Marc

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		F(1)		7,914	D	$30.11	341,852(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2025 and does not represent a sale.

2. Includes 529 shares of common stock purchased on July 31, 2025 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Marc Stapley report on the Form 4 for Veracyte (VCYT)?

He reported 7,914 shares withheld to satisfy tax withholding on vested restricted stock units; this was recorded as a non-sale on 09/02/2025.

Was the 7,914-share transaction a sale of Veracyte stock?

No. The Form 4 clarifies the shares were withheld to cover taxes related to RSU vesting and do not represent a sale.

How many Veracyte shares did Stapley own after the transaction?

341,852 shares beneficially owned following the withholding, which includes 529 shares bought on 07/31/2025 under the ESPP.

What price is reported on the Form 4 for the withheld shares?

$30.11 per share is the price shown in the transaction record for the 7,914 withheld shares.

When was the Form 4 filed or signed?

The form shows an attorney-in-fact signature dated 09/04/2025 reflecting the reporting of the 09/02/2025 transaction.